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There are no published guidelines for treatment of ocular surface squamous neoplasia (OSSN). Also, clinical spectrum of OSSN varies significantly between different continents like Africa and North America or Australia [2] . Clinical presentation is significantly delayed in resource-constrained countries, and hence use of conservative management options like plaque brachytherapy are not only limited by availability but also by feasibility.
The conventional method of treatment for OSSN is wide local surgical excision using a 'no touch technique' and cryotherapy of conjunctival edges. Topical treatment with chemotherapeutic agents and interferons has become popular in the past 1-2 decades due to the inherent benefits of topical treatment-treatment of a complete ocular surface, thus reducing the chances of microscopic residual disease, lesser side effects of treatment as compared to surgical excision, especially in giant or diffuse tumors and the relative ease of administering treatment. Traditionally, enucleation is done for tumors with intraocular extension and exenteration for OSSN with orbital extension.
We agree with the authors that, technology-dependent treatment modalities, like plaque brachytherapy and proton beam therapy may not be available in resource-constrained countries. There are adequate reports in literature to show that brachytherapy effectively controls OSSN invading into the ocular coats and hence may be used as an adjuvant treatment in cases with incomplete tumor resection (Table 1 ) (the same has been added in the treatment options for grade II tumor in the revised table) [3] . However, its use in OSSN with overt (obvious on imaging (UBM) or clinically) intraocular extension is still being explored and needs to be evaluated in further studies [4] . We, at our center are now using adjuvant plaque brachytherapy in cases of invasive SCC, where there is microscopic residual disease in the ocular coats after surgery.
The proposed classification attempts to address the concerns with AJCC classification, as reported by previous studies and intends to give a rough guideline for treatment based on most commonly available treatment modalities [4] . While enucleation and exenteration remain the most common method of treatment for tumor with ocular and orbital extension, respectively, the treatment scenario for OSSN with ) . Till the time, further studies evaluate and define the role of other possible treatment options for intraocular and orbital disease like external beam radiotherapy, brachytherapy, or intraorbital interferon injections for a possible staged management approach; this classification may help guide treatment with the more established treatment options [5, 6] .
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